Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio is a clinical-stage biotech company with a strong focus on developing therapies for serious diseases associated with dysregulated immune responses. Their lead product candidate, GRI-0621, has shown positive results in treating idiopathic pulmonary fibrosis (IPF) and has potential for use in other autoimmune disorders. Recent fiscal Q1 results were in line with expectations, indicating solid financial management. However, success in clinical trials and regulatory approvals are key factors in future growth and share price.

Bears say

GRI Bio is a clinical-stage biopharmaceutical company with a focus on developing therapies for diseases related to immune response. Despite positive top-line data for their lead drug GRI-0621, concerns surrounding the long development and commercialization process and high risks associated with clinical trials and commercial failures, lead to an adjusted EPS estimate and a lower price target. However, the company's current valuation presents an attractive opportunity for potential investors looking to balance the high risks with the potential for significant upside.

GRI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 1 analysts, GRI has a Strong Buy consensus rating as of Jun 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.